CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
Rhea-AI Summary
CytoDyn (OTCQB: CYDY) has initiated dosing in its Phase II clinical trial evaluating leronlimab for relapsed/refractory microsatellite stable colorectal cancer (CRC). The trial, conducted in partnership with Syneos Health across eight clinical sites, is led by Dr. Ben Weinberg from Georgetown University. According to WHO data, colorectal cancer represents the third most common cancer globally, with approximately 1.9 million new cases and 900,000 deaths annually.
The study builds on CytoDyn's previous research showing potential clinical benefits of leronlimab in relapsed CRC patients and aims to evaluate its mechanism of action in solid tumor oncology. The company's strategy is influenced by promising survival rates observed in prior metastatic triple-negative breast cancer studies.
Positive
- First patient dosed in Phase II trial for colorectal cancer treatment
- Partnership with Syneos Health and engagement of eight clinical sites
- Building on previous promising research in CRC and breast cancer
- Targeting large market opportunity with 1.9 million new CRC cases annually
Negative
- Early-stage Phase II trial with uncertain outcomes
- Operating in highly competitive oncology market
- Trading on OTCQB market rather than major exchange
News Market Reaction
On the day this news was published, CYDY gained 4.65%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health
VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer (“CRC”).
In partnership with Syneos Health, the Company has engaged eight clinical sites and counting, and patient enrollment and processing efforts are underway. The lead principal investigator for the trial is Dr. Ben Weinberg, MD, from Georgetown University and the MedStar Health Alliance.
According to the World Health Organization’s International Agency for Research on Cancer (“IARC”), colorectal cancer is the third most common cancer type worldwide, and the second most common cause of cancer-related deaths globally. IARC’s most recently published figures estimate that there are about 1.9 million new cases of colorectal cancer and more than 900,000 deaths due to colorectal cancer worldwide each year. The IARC also noted that the incidence rates of colorectal cancer in people younger than 50 years old have been increasing for at least 20 years, with some sources dating the increase trend back 30 years or more.
“Dosing the first patient in our Phase II CRC trial is a significant step forward in our mission to bring innovative treatment options to patients facing this challenging disease. This milestone reflects the dedication of our team and clinical partners, and we look forward to advancing this study to better understand the potential impact of our therapy across solid tumor oncology,” said Dr. Jacob Lalezari, CEO of CytoDyn.
The study builds on the Company’s prior research demonstrating the potential clinical benefit of leronlimab in patients with relapsed CRC, and will also further the evaluation of the potential for the Company’s recently announced mechanism of action for leronlimab in solid tumor oncology. Given the promising survival rates observed in the Company’s prior studies in patients with metastatic triple-negative breast cancer and the Company’s ongoing clinical investigation efforts in CRC, CytoDyn views its current line of scientific evaluation as the most expeditious path to determining how broadly applicable this mechanism may prove to be across various solid tumors.
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn has studied leronlimab in multiple therapeutic areas, including oncology, infectious disease, and autoimmune conditions.
About Syneos Health
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. Syneos Health translates unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. Syneos Health brings a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together, Syneos Health shares insights, uses the latest technologies and applies advanced business practices to speed its customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. To learn more about how Syneos Health is shortening the distance from lab to life®, visit syneoshealth.com.
Media Contacts
CytoDyn
Riyaz Lalani
Gagnier Communications
CytoDyn@gagnierfc.com
FAQ
What is the latest clinical trial announcement from CytoDyn (CYDY)?
Who is leading CytoDyn's Phase II colorectal cancer trial?
How many clinical sites are involved in CytoDyn's colorectal cancer trial?
What is the market potential for CytoDyn's colorectal cancer treatment?
What previous research supports CytoDyn's colorectal cancer trial?
